Nkarta, Inc. - NKTX Earnings per share for the last twelve months

Official company branding of Nkarta, Inc. (NKTX)

Nkarta, Inc. (NKTX) competes in the leukemia and solid tumor therapy segment by developing safe NK-cell drugs. Earnings per share over the last four quarters demonstrate resilience, with the current value standing at -1.75. Growth is driven by the expansion of clinical trials to capture the biotech market, while its independence from macroeconomic factors makes the asset a reliable defensive tool due to stable demand for innovation.

NKTX Nkarta Corp Net earnings per one share for the last twelve months (07/04/2022 - 11/16/2026)

Financial and market metric breakdowns for Nkarta, Inc. (NKTX)

- current quotes and average value forecast:
Analysis of all company metrics:Nkarta (NKTX)
Mass-produced product of Nkarta Corp

For Nkarta, Inc. (NKTX), whose operational expenditures for NK-therapy development are already priced in by the market, annual net income per share serves as an indicator of the transition from the investment stage to monetization. This metric determines the portion of real income per share over 12 months, allowing investors to distinguish sustainable business growth from a temporary reduction in costs.